A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in NHL Subjects

Non-Hodgkin's B-cell Lymphoma Clinical Trial

Official title:

A Study Evaluating Safety and Efficacy of C-CAR039 Treatment in Relapsed or Refractory NHL Subjects

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04317885
• Other study ID #: 0702-015
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: November 5, 2019
• Est. completion date: December 30, 2023

Study information

• Verified date: May 2023
• Source: Shanghai Tongji Hospital, Tongji University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR039 in treatment of relapsed or refractory NHL patients

Description:

This study plans to enroll 25 patients to assess the safety and efficacy of C-CAR039. Subjects who meet the eligibility criteria will receive a single dose of C-CAR039 injection.

The study will include the following sequential phases: Screening, Apheresis and C-CAR039 manufacturing, Bridging (if needed), Baseline, lymphodepletion, C-CAR039 infusion, and Follow-up Visit.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 25
• Est. completion date: December 30, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• 1. Volunteered to participate in this study and signed informed consent

• 2. Age 18-75 years old, male or female

• 3. CD19 or CD20 positive DLBCL (including PMBCL and tFL), FL and MCL confirmed by cytology or histology according to WHO2016 criteria. For CD20-positive subjects, they should have received at least one regimen containing anti-CD20-targeted therapy (such as rituximab). If they do not complete the regimen due to intolerance, the cause should be recorded.

• 4. Relapsed or refractory disease after = 2 lines (for FL, at least 3 lines) of standard therapy or relapsed after autologous stem cell transplantation (ASCT)

• 5. At least one measurable lesion (LDi = 1.5 cm);

• 6. At least two weeks from last treatment (radiation, chemotherapy, mAb, etc) to apheresis;

• 7. LVEF= 50% (ECHO)

• 8. No active pulmonary infections, normal or mild impaired pulmonary function and SpO2=92%

• 9. Laboratory criteria: ANC=1.0×109/L; Platelets=50×109/L; Serum total bilirubin =1.5x ULN; Creatinine= ULN; AST and ALT=3x ULN

• 10. No contraindications of apheresis;

• 11. Expected survival = 3months

• 12. ECOG score 0 or 1

Exclusion Criteria:

• 1. Have a history of allergy to cellular products;

• 2. According to the NYHA cardiac function grading standards, patients with grade III or IV cardiac dysfunction;

• 3. A history of craniocerebral trauma, disturbance of consciousness, epilepsy, cerebrovascular ischemia, cerebrovascular hemorrhagic disease, etc.;

• 4. Patients with central nervous system involvement;

• 5. Patients with autoimmune diseases, immunodeficiency or other conditions requiring immunosuppressive therapy;

• 6. Received allogeneic hematopoietic stem cell transplantation before;

• 7. Previous use of any CAR T cell product or other genetically modified T cell therapy;

• 8. Autologous stem cell transplantation within 6 weeks before infusion;

• 9. Severe active infections (except for simple urinary tract infections, bacterial pharyngitis), or currently undergoing intravenous infusion of antibiotics. However, prophylactic antibiotic, antiviral and antifungal infection treatments are permissible;

• 10. Live vaccination within 4 weeks prior to apheresis;

• 11. People infected with HIV, HBV, HCV and TPPA/RPR, and carriers with HBV;

• 12. A history of alcohol abuse, drug use or mental illness;

• 13. Subjects who are not sterilized and have any of the following conditions:

1. are pregnant/lactating; or

2. planned pregnancy during the trial; or

3. being fertile and unable to use effective contraception;

• 14. Severe hypersensitivity to fludarabine or cyclophosphamide;

• 15. A history of other primary cancers other than the following:

1. Non-melanoma tumors such as basal cell carcinoma of the skin that are cured by excision

2. Cured in situ cancers such as cervical, bladder, or breast cancer

• 16. The investigators consider that the subject has other conditions that are not suitable for this trial.

Related Conditions & MeSH terms

• Lymphoma, B-Cell
• Non-Hodgkin's B-cell Lymphoma

Intervention

Biological:
• Prizloncabtagene Autoleucel
Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously

Locations

Country	Name	City	State
China	Shanghai Tongji Hospital, Tongji University School of Medicine	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Tongji Hospital, Tongji University School of Medicine	Cellular Biomedicine Group Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence and severity of adverse events	Incidence and severity of adverse events after CAR-T infusion	Up to 12 weeks after C-CAR039 infusion
Secondary	Overall Response rate (ORR)	Complete response (CR) rate plus partial response (PR) rate by Lugano 2014 criteria	Up to 24 Months after C-CAR039 infusion
Secondary	Duration of response (DOR)	The time from the date of first response (PR or CR) to the date of disease progression or death after C-CAR039 infusion	Up to 24 Months after C-CAR039 infusion
Secondary	Progression-free survival (PFS)	The time from C-CAR039 infusion to the date of progression as assessed by Lugano 2014 criteria or death	Up to 24 Months after C-CAR039 infusion
Secondary	Overall survival (OS)	The time from C-CAR039 infusion to the date of death	Up to 24 Months after C-CAR039 infusion